ABBV241227P177500
- 2.58
- +0.27+11.69%
AbbVie Newsroom
AbbVie Call Volume Above Normal and Directionally Bullish
AbbVie (ABBV) Benefitted From Top-Line Growth From Its Immunosuppressive Drugs
Is AbbVie Stock a Buy?
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
AbbVie Insiders Sell US$56m Of Stock, Possibly Signalling Caution
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
AbbVie Hits 4-week Low
AbbVie's Atogepant And OnabotulinumtoxinA Receive Strong Recommendations In The Newly Updated Canadian Headache Society Migraine Prevention Guideline; A Strong Recommendation Was Issued When An Intervention Was Deemed Suitable For The Majority Of...
Express News | Abbvie's Atogepant and Onabotulinumtoxina Receive Strong Recommendations in the Newly Updated Canadian Headache Society (Chs) Migraine Prevention Guideline
Is AbbVie Inc. (ABBV) the Safest Dividend Stock to Invest In Now?
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year
Dow Breaks Downward Spiral, with FOMC Rate Cut on Deck | Live Stock
AbbVie's Tavapadon Achieves Positive Topline Results in Phase III TEMPO-2 Trial
Investors Heavily Search AbbVie Inc. (ABBV): Here Is What You Need to Know
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
Tuesday, Tech Pulls Back, While Traders Await FOMC Rate | Wall Street Today
AbbVie Analyst Ratings
Tuesday Tech Pull Back After Nasdaq and Bitcoin Record | Live Stock